Compare AU
Compare HJZP vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Hejaz Property Fund (Managed Fund) (HJZP) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
HJZP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 81 |
Median incremental investment | $719.64 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,487.62 | $1,386.00 |
Average age group | 26 - 35 | > 35 |
Key Summary
HJZP | CURE | |
|---|---|---|
Strategy | HJZP.AX was created on 2022-10-17 by M&G . The fund's investment portfolio concentrates primarily on real estate equity. The Funds investment approach is to research, screen, and then select quality investments, across Australian and international Real Estate Investment Trusts (REITS). | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Digital Realty Trust Inc (19.34 %) American Homes 4 Rent Class A (9.39 %) Dexus Industria REIT (8.28 %) | Neurocrine Biosciences Inc (2.58 %) AbbVie Inc (2.42 %) Gilead Sciences Inc (2.42 %) |
Top 3 industries | Real Estate (100.00 %) Other (16.15 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (61.96 %) Australia (23.42 %) Mexico (8.16 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 1.5 % | 0.45 % |
Key Summary
HJZP | CURE | |
|---|---|---|
Issuer | M&G | Global X |
Tracking index | MSCI World REITs Index - AUD - Australian Dollar - Benchmark TR Net | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 1.5 % | 0.45 % |
Price | $0.845 | $49.49 |
Size | N/A | $36.399 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.16 % | 4.24 % |
Market | ASX | ASX |
First listed date | 16/10/2022 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
HJZP | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 81 |
Median incremental investment | $719.64 | $620.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,487.62 | $1,386.00 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
HJZP | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
HJZP | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |